Researchers have found bariatric surgery to be more cost-effective for treating patients with obesity compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to new study ...

Real-world data showed high incidence of hair loss among GLP-1 receptor agonist users, but the phenomenon is probably an ...

Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...

Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved ...

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits1This approval is based on results from the SOUL clinical trial, ...

Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg ...

GLP-1 RAs were associated with positive effects on intracranial hypertension management, including reduced symptoms and treatment burden.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

GLP-1 receptor agonists vs other second-line therapies were not associated with an increased thyroid cancer risk among patients with type 2 diabetes.